Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Leramistat
NCT06379958Phase 1Recruiting
- Sponsor
- Modern Biosciences
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Leramistat in rheumatoid arthritis (RA) (4 arms), sponsored by Modern Biosciences. Primary endpoints: Area under the curve - AUC0-t at 8.5 weeks, Area under the curve - AUC0-24h at 8.5 weeks and 7 more. Started Apr 2024; status: recruiting.
02
Drugs
Leramistat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06379958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06379958.